Myokardia Inc (MYOK) Given Consensus Rating of “Buy” by Brokerages
Myokardia Inc (NASDAQ:MYOK) has been assigned an average rating of “Buy” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $55.67.
A number of research analysts have recently issued reports on the company. BidaskClub raised Myokardia from a “hold” rating to a “buy” rating in a report on Saturday, February 17th. ValuEngine raised Myokardia from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Credit Suisse Group reissued an “outperform” rating and issued a $60.00 target price on shares of Myokardia in a report on Thursday, January 18th. Zacks Investment Research lowered Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, JPMorgan Chase & Co. assumed coverage on Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 target price on the stock.
In related news, Director Kevin P. Starr sold 816,326 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total transaction of $34,285,692.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Anastasios Gianakakos sold 5,000 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the transaction, the insider now directly owns 79,390 shares in the company, valued at approximately $4,763,400. The disclosure for this sale can be found here. In the last three months, insiders sold 845,326 shares of company stock worth $35,676,662. Corporate insiders own 33.40% of the company’s stock.
Myokardia (MYOK) traded down $0.15 during trading hours on Wednesday, hitting $60.95. The stock had a trading volume of 208,055 shares, compared to its average volume of 390,031. Myokardia has a 1-year low of $10.80 and a 1-year high of $62.83.
WARNING: “Myokardia Inc (MYOK) Given Consensus Rating of “Buy” by Brokerages” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/myokardia-inc-myok-given-consensus-rating-of-buy-by-brokerages/1909464.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.